Equity Investment Corp Sells 52,395 Shares of Sanofi (NASDAQ:SNY)

Equity Investment Corp reduced its stake in Sanofi (NASDAQ:SNY) by 2.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 2,406,189 shares of the company’s stock after selling 52,395 shares during the quarter. Sanofi makes up 2.7% of Equity Investment Corp’s investment portfolio, making the stock its 11th largest holding. Equity Investment Corp owned 0.09% of Sanofi worth $116,050,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also bought and sold shares of the stock. Abel Hall LLC boosted its position in Sanofi by 1.8% in the fourth quarter. Abel Hall LLC now owns 10,990 shares of the company’s stock worth $530,000 after purchasing an additional 194 shares during the last quarter. PDS Planning Inc boosted its holdings in shares of Sanofi by 3.1% in the 3rd quarter. PDS Planning Inc now owns 6,643 shares of the company’s stock worth $383,000 after buying an additional 200 shares during the last quarter. Financial Advocates Investment Management grew its position in Sanofi by 3.4% during the third quarter. Financial Advocates Investment Management now owns 6,327 shares of the company’s stock valued at $365,000 after buying an additional 206 shares during the period. Angeles Investment Advisors LLC increased its holdings in Sanofi by 1.9% during the third quarter. Angeles Investment Advisors LLC now owns 11,323 shares of the company’s stock worth $653,000 after buying an additional 210 shares during the last quarter. Finally, Keudell Morrison Wealth Management increased its stake in shares of Sanofi by 1.7% during the 4th quarter. Keudell Morrison Wealth Management now owns 12,928 shares of the company’s stock worth $624,000 after purchasing an additional 217 shares during the last quarter. 14.04% of the stock is currently owned by institutional investors.

Sanofi Stock Performance

NASDAQ:SNY opened at $54.95 on Thursday. The business’s fifty day moving average is $51.38 and its 200 day moving average is $52.58. The firm has a market cap of $139.45 billion, a price-to-earnings ratio of 22.07, a PEG ratio of 1.01 and a beta of 0.57. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. Sanofi has a 52-week low of $45.22 and a 52-week high of $58.97.

Sanofi (NASDAQ:SNY) last posted its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. Research analysts predict that Sanofi will post 4.36 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on SNY. Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. StockNews.com downgraded Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Finally, Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Two analysts have rated the stock with a hold rating, one has assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $60.00.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.